Oncology Activities
HER2-Directed Therapy in Metastatic Breast Cancer: Pharmacist Involvement to Optimize Care
0290-0000-20-404-H01-P
This webinar will prepare pharmacists to identify and manage adverse effects as well as individualize treatment for patients receiving therapies for HER2+ metastatic breast cancer.
0.75
Connecting Biology to Prognosis and Treatment in Non-Hodgkin Lymphoma
0290-0000-20-331-H01-P
This activity will focus on genetic mutations present in various forms of NHL. Additionally, the rationale behind treatment decisions, with an emphasis on national guidelines recommendations, will be discussed.
1.00
Forging New Treatment Pathways in Relapsed/Refractory Follicular Lymphoma
0290-0000-20-332-H01-P
This activity will focus on oral oncolytics used in the treatment of R/R follicular lymphoma, with a focus on novel therapies.
1.00
Advances in the Management of Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Nontransplant Candidates
0290-0000-20-333-H01-P
This activity will explore the clinical data associated with the treatment of R/R DLBCL and will also highlight the mechanism of action, potential drug interactions, and adverse effects associated with mAb and antibody-drug conjugate therapies.
1.00